We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Mar 2022 - 09 Mar 2022
Virtual Venue

Bacterial Communities Diverge in The Lower Airways of CF Children

By LabMedica International staff writers
Posted on 23 Dec 2021
Print article
Image: The EZ1 Advanced XL performs automated nucleic acid purification for a wide range of sample types relevant for molecular diagnostics, human identity testing, and gene expression analysis (Photo courtesy of Qiagen).
Image: The EZ1 Advanced XL performs automated nucleic acid purification for a wide range of sample types relevant for molecular diagnostics, human identity testing, and gene expression analysis (Photo courtesy of Qiagen).
Chronic airway infection and inflammation resulting in progressive, obstructive lung disease is the leading cause of morbidity and mortality in people with cystic fibrosis (CF). Culture-independent, molecular approaches have broadened the view from a few individual pathogens to more complex and dynamic polymicrobial communities.

In infants and young children with CF, culture-independent next-generation sequencing approaches have been useful in describing the upper airway microbiota, and previous studies have shown that younger patients have higher diversity which decreases as lung disease progresses. Longitudinal analysis of infant samples has identified changes in microbial composition and diversity in the first two years of life.

A team of Pulmonologists and Pediatricians, led by those at Lurie Children’s Hospital of Chicago (Chicago, IL, USA), and their colleagues evaluated clinical data and bronchoalveolar lavage fluid (BALF) samples from 191 participants up to age 21 years. Sixty-three patients had cystic fibrosis (mean age, 9.7 years; 65% female). DNA was extracted from BALF samples using the Qiagen EZ1 Advanced automated extraction platform (Qiagen, Valencia, CA, USA). Total bacterial load (TBL) was assessed using the quantitative PCR assay. Bacterial profiles were determined by amplification of the V1/V2 variable region (27F/338R) of the 16S rRNA gene. Operational taxonomic units (OTUs) were produced by clustering sequences with identical taxonomic assignments. Illumina paired-end sequencing was performed on the MiSeq platform using a 500-cycle version 2 reagent kit (Illumina, San Diego, CA, USA).

The investigators reported that higher bacterial load and lower microbial diversity in samples from patients with cystic fibrosis. In addition, these samples also had a divergence from disease controls aged 2 to 5 years and higher neutrophilic inflammation relative to bacterial burden, according to the results. They observed an increase in traditional cystic fibrosis pathogens and decreased Streptococcus mitis, S. oralis and S. pneumoniae species in the samples from older participants with cystic fibrosis. The most prevalent species-level taxa were S. mitis/oralis/pneumoniae (52%) and Prevotella melaninogenica (44%). There was increased diversity in the heterogeneous disease controls independent of cystic fibrosis diagnosis and indication.

Theresa Laguna, MD, MSCS, an Associate Professor of Pediatrics and senior author of the study, said, “Establishing key age-related differences in lower airway bacterial communities and inflammation in patients with CF, especially during early childhood, may give us a window of opportunity for earlier and more precise treatment. If we can prevent worse infections, we could improve the quality of life and potentially expand the life expectancy of patients with CF.”

The authors concluded that they had found distinctions between the airway microbiomes of CF and disease control subjects in a pediatric population that can inform future studies. By using 16S, they characterized complex polymicrobial communities in the lower airway from infancy up to young adulthood in people with and without CF. The study was published on October 6, 2021 in the journal PLOS ONE.

Related Links:
Lurie Children’s Hospital of Chicago
Qiagen
Illumina


Gold Supplier
Molecular Diagnostic System
iPonatic
New
Multi-Tube Vortexer
BenchMixer XL
New
Immunodiagnostic Analyzer
LiCA 5000
New
Benchtop Centrifuge
ROTOFIX 46 | 46 H

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more

Hematology

view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.